Jennifer Zachary - Merck General Counsel

MRK Stock  ARS 26,920  189.00  0.71%   

Executive

Ms. Jennifer Zachary is Executive Vice President, General Counsel of the Company, effective April 16, 2018. Zachary is currently a partner at Covington Burling in the firm food, drug, and device practice group where she advises a wide range of manufacturers and industry trade associations on FDA requirements for the development, manufacture, and distribution of prescription and overthecounter drugs, biologics, and medical devices. Zachary began her career in FDA Office of Chief Counsel, where she served as an Associate Chief Counsel for Enforcement from 2005 to 2011. Zachary also served as a Special Assistant U.S. Attorney in the Civil Division of the U.S. Attorney Office for the District of Columbia. since 2018.
Age 45
Tenure 6 years
Phone908 740 4000
Webhttps://www.merck.com

Merck Management Efficiency

The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 26.97 B in total debt with debt to equity ratio (D/E) of 97.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Merck Company has a current ratio of 1.34, which is within standard range for the sector. Debt can assist Merck until it has trouble settling it off, either with new capital or with free cash flow. So, Merck's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Merck Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Merck to invest in growth at high rates of return. When we think about Merck's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Pablo EssesTelecom Argentina
56
Jaco BoshoffHarmony Gold Mining
47
Sandra AuditoreCompania de Transporte
N/A
Fabian FernandezTelecom Argentina
N/A
Walter PardiquienTransportadora de Gas
57
Jose ZulianiTransportadora de Gas
56
Alejandro SanchezAgrometal SAI
N/A
Carlos AlmagroTransportadora de Gas
N/A
Rodolfo OReillyCompania de Transporte
N/A
Abre VuurenHarmony Gold Mining
56
Eduardo ContteTelecom Argentina
62
Tumi LegobyeHarmony Gold Mining
N/A
Dan LesnakUnited States Steel
N/A
Alejandro MassaTelecom Argentina
63
Robert HartHarmony Gold Mining
42
Maria BonelliTelecom Argentina
N/A
Colleen DarraghUnited States Steel
45
Pablo MartinTelecom Argentina
54
Sergio FaraudoTelecom Argentina
59
Melanie NaidooVermaakHarmony Gold Mining
42
Gonzalo HitaTelecom Argentina
53
It operates through four segments Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. MERCK INC operates under Drug Manufacturers - Major classification in Argentina and is traded on Buenos-Aires Stock Exchange. It employs 69000 people. Merck Company (MRK) is traded on Buenos Aires Exchange in Argentina and employs 44 people.

Management Performance

Merck Company Leadership Team

Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Glocer, Independent Director
Craig Thompson, Independent Director
Cristal Downing, Ex Officer
Jennifer Zachary, General Counsel
Rochelle Lazarus, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Paul Rothman, Director
Mary Coe, Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Caroline Litchfield, Ex CFO
Joseph Romanelli, IR Contact Officer
Mirian GraddickWeir, Executive Vice President - Human Resources
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Jennifer Mauer, VP Communications
Leslie Brun, Independent Director
Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health
Inge Thulin, Director
Pamela Craig, Director
Patricia Russo, Independent Director
David Williams, Ex Officer
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Lisa LeCointeCephas, VP Officer
Robert Davis, CFO and Executive VP
Robert Kidder, Independent Director
Thomas Cech, Independent Director
Michael Nally, Chief Marketing Officer
Peter Dannenbaum, VP Relations
Clark Golestani, Executive Vice President CIO
William Harrison, Lead Independent Director
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Steven Mizell, Chief Human Resource Officer
Jim Scholefield, Chief Information and Digital Officer
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman, CEO and Pres
Frank Clyburn, Chief Commercial Officer
Robert JD, Pres Chairman

Merck Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Money Managers
Screen money managers from public funds and ETFs managed around the world
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Valuation
Check real value of public entities based on technical and fundamental data
Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.